article
GSK: A Lifetime in Fluorescence
GSK's top investigators explain why the data quality offered by Fluorescence lifetime detection technology for drug discovery applications is superior…
List view / Grid view
Antibodies
article
Antibodies In-Depth Focus 2017
Lone Friis and David Matthews discuss developability assessment of therapeutic antibodies, and Negin Mokhtari and colleagues explain nanoparticle-mediated enzyme delivery for application in cancer therapy...
article
Q&A: Lou Matis on bispecific antibodies
Drug Target Review Editor Steve Bremer talks to Pieris’ Chief Development Officer Lou Matis about bispecific antibodies.
article
Drug Target Review – Issue #1 2017
Included in this issue: Importance of building patient trust; Vaccines & Immunology; Oncology; Assays; Biomarkers; and Antibodies...
article
Developability assessment of therapeutic antibodies
Developability assessment is a broad term covering the evaluation of potential therapeutic candidates’ drug-like properties, manufacturability and safety profile. It is important to carry out this assessment as early as possible in the pre-clinical stage development to select the candidate with the most stable profile. This can minimise the risks…
whitepaper
Application Note: An Easy-to-Use Assay to Measure Target Cell Death by Antibody Dependent Cellular Phagocytosis (ADCP)
With an increasing industry focus on antibody drugs, there is an ever greater need for functional bioassays that interrogate the various mechanisms of action (MOA) for the therapeutic antibody...
product
Cisbio Bioassays Toolbox products and services
4 October 2016 | By Cisbio
A comprehensive line of ready-to-use HTRF toolbox reagents labeled with HTRF fluorescent dyes for studying molecular interactions using time-resolved fluorescence energy transfer...
news
Using PD-L1 for immunotherapy?
21 September 2016 | By Abcam
PD-L1 [28-8] (ab205921) is an ideal tool to quantify PD-L1 expression in patients for PD-1 based therapies....
article
Practical application of in vivo optical imaging in biotherapeutic biodistribution analyses
As advances in protein engineering technology have led to the production of novel and more structurally complex biopharmaceuticals, the ability of these drugs to smoothly traverse the body and arrive at their intended target site has become more unpredictable...
news
Inducing antibodies could lead to a universal flu vaccine
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Scientists have identified three types of vaccine-induced antibodies that can neutralise diverse strains of the flu virus that infect so many each year...
news
Sorrento and Servier team up to develop anti-PD-1 antibody
12 July 2016 | By Victoria White, Digital Content Producer
Sorrento and Servier are teaming up to develop, manufacture and commercialise products using Sorrento's monoclonal antibody, STI-A1110...
news
Tri-I TDI expands focus to include antibody drug discovery
17 June 2016 | By Victoria White, Digital Content Producer
Tri-I TDI will extend its current relationship with Takeda from the realm of small molecule discovery into the new research area of antibody drug discovery...
whitepaper
Whitepaper: Further considerations of antibody validation and usage – how to avoid reviewer challenges
The effective use of antibodies in research assays has always depended on multiple factors that determine the accuracy and precision of the component reagents...
news
NIBSC – MHRA, go under the Microscope in the Run-up to their Opening Keynote at Allergies 2016
19 May 2016 | By SMI
SMi are thrilled to have Dr Carl Dolman from the National Institute for Biologics, Standard and Control (NIBSC), a centre of the MHRA, present an opening keynote at the 3rd annual Allergies conference when it returns to London on 6th & 7th July...
news
A new clue in lupus autoantibody production
12 April 2016 | By Victoria White, Digital Content Producer
Researchers have discovered that interferon gamma could hold the key to understanding how harmful autoantibodies form in lupus patients...
